179 related articles for article (PubMed ID: 28936569)
41. Optimizing treatment outcomes with regorafenib: personalized dosing and other strategies to support patient care.
Grothey A; George S; van Cutsem E; Blay JY; Sobrero A; Demetri GD
Oncologist; 2014 Jun; 19(6):669-80. PubMed ID: 24821824
[TBL] [Abstract][Full Text] [Related]
42. Meta-analysis on the risk of fatal adverse events by bevacizumab, cetuximab, and panitumumab in 31 randomized trials including 25,000 patients with colorectal carcinoma.
Chen J; Wang J; Ni T; He H; Zheng Q
Medicine (Baltimore); 2020 Jun; 99(25):e19908. PubMed ID: 32569154
[TBL] [Abstract][Full Text] [Related]
43. The safety of regorafenib for the treatment of gastrointestinal stromal tumors.
Rutkowski P; Stępniak J
Expert Opin Drug Saf; 2016 Jan; 15(1):105-16. PubMed ID: 26651387
[TBL] [Abstract][Full Text] [Related]
44. Fatal adverse events with molecular targeted agents in the treatment of advanced hepatocellular carcinoma: a meta-analysis of randomized controlled trials.
Li X; Wan J; Wu Z; Tu J; Hu Y; Wu S; Lou L
Drug Des Devel Ther; 2018; 12():3043-3049. PubMed ID: 30271119
[TBL] [Abstract][Full Text] [Related]
45. [Regorafenib approved in Metastatic Colorectal cancer].
André T; Dumont SN
Bull Cancer; 2013 Oct; 100(10):1027-9. PubMed ID: 24047557
[TBL] [Abstract][Full Text] [Related]
46. Regorafenib induced severe toxic hepatitis: characterization and discussion.
Sacré A; Lanthier N; Dano H; Aydin S; Leggenhager D; Weber A; Dekairelle AF; De Cuyper A; Gala JL; Humblet Y; Sempoux C; Van den Eynde M
Liver Int; 2016 Nov; 36(11):1590-1594. PubMed ID: 27500989
[TBL] [Abstract][Full Text] [Related]
47. Regorafenib: A Review of Its Use in Patients with Advanced Gastrointestinal Stromal Tumours.
Shirley M; Keating GM
Drugs; 2015 Jun; 75(9):1009-17. PubMed ID: 25998375
[TBL] [Abstract][Full Text] [Related]
48. Regorafenib.
Ettrich TJ; Seufferlein T
Recent Results Cancer Res; 2014; 201():185-96. PubMed ID: 24756792
[TBL] [Abstract][Full Text] [Related]
49. Adverse events risk associated with regorafenib in the treatment of advanced solid tumors: meta-analysis of randomized controlled trials.
Yin X; Yin Y; Shen C; Chen H; Wang J; Cai Z; Chen Z; Zhang B
Onco Targets Ther; 2018; 11():6405-6414. PubMed ID: 30323618
[TBL] [Abstract][Full Text] [Related]
50. Clinical Features of Regorafenib-induced Liver Injury in Japanese Patients From Postmarketing Experience.
Uetake H; Sugihara K; Muro K; Sunaya T; Horiuchi-Yamamoto Y; Takikawa H
Clin Colorectal Cancer; 2018 Mar; 17(1):e49-e58. PubMed ID: 29074353
[TBL] [Abstract][Full Text] [Related]
51. A Systematic Review and Meta-analysis of Retrospective Series of Regorafenib for Treatment of Metastatic Colorectal Cancer.
Mercier J; Voutsadakis IA
Anticancer Res; 2017 Nov; 37(11):5925-5934. PubMed ID: 29061771
[TBL] [Abstract][Full Text] [Related]
52. Adverse event management strategies: optimizing treatment with regorafenib in patients with metastatic colorectal cancer.
Mitchell J; Khoukaz T; McNeal D; Brent L
Clin J Oncol Nurs; 2014 Apr; 18(2):E19-25. PubMed ID: 24675266
[TBL] [Abstract][Full Text] [Related]
53. Incidence and Risk of Fatal Adverse Events in Cancer Patients Treated With Vascular Endothelial Growth Factor Receptor 2-Targeted Agents: A Meta-Analysis With Trial Sequential Analysis of Randomized Controlled Trials.
Zhao B; Zhao H; Zhao J
Front Med (Lausanne); 2019; 6():176. PubMed ID: 31440509
[No Abstract] [Full Text] [Related]
54. Treatment-related mortality with everolimus in cancer patients.
Wesolowski R; Abdel-Rasoul M; Lustberg M; Paskell M; Shapiro CL; Macrae ER
Oncologist; 2014 Jun; 19(6):661-8. PubMed ID: 24794158
[TBL] [Abstract][Full Text] [Related]
55. Severe and fatal adverse events of immune checkpoint inhibitor combination therapy in patients with metastatic renal cell carcinoma: a systematic review and meta-analysis.
Feng YN; Xie GY; Xiao L; Mo DC; Huang JF; Luo PH; Liang XJ
Front Immunol; 2023; 14():1196793. PubMed ID: 37404816
[TBL] [Abstract][Full Text] [Related]
56. Off-target effects and clinical outcome in metastatic colorectal cancer patients receiving regorafenib: The TRIBUTE analysis.
Giampieri R; Prete MD; Prochilo T; Puzzoni M; Pusceddu V; Pani F; Maccaroni E; Mascia R; Baleani MG; Meletani T; Berardi R; Lanzillo AM; Mariotti S; Zaniboni A; Cascinu S; Scartozzi M
Sci Rep; 2017 Apr; 7():45703. PubMed ID: 28378839
[TBL] [Abstract][Full Text] [Related]
57. Arterial thromboembolism in cancer patients treated with cisplatin: a systematic review and meta-analysis.
Proverbs-Singh T; Chiu SK; Liu Z; Seng S; Sonpavde G; Choueiri TK; Tsao CK; Yu M; Hahn NM; Oh WK; Galsky MD
J Natl Cancer Inst; 2012 Dec; 104(23):1837-40. PubMed ID: 23093559
[TBL] [Abstract][Full Text] [Related]
58. Fatal Adverse Events Associated With Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer: A Systematic Review and Meta-Analysis.
Yu X; Zhang X; Yao T; Zhang Y; Zhang Y
Front Med (Lausanne); 2021; 8():627089. PubMed ID: 33659263
[No Abstract] [Full Text] [Related]
59. An updated meta-analysis of fatal adverse events caused by bevacizumab therapy in cancer patients.
Huang H; Zheng Y; Zhu J; Zhang J; Chen H; Chen X
PLoS One; 2014; 9(3):e89960. PubMed ID: 24599121
[TBL] [Abstract][Full Text] [Related]
60. Treatment-related severe and fatal adverse events with molecular targeted agents in the treatment of advanced gastric cancer: a meta-analysis.
Wang L; Liu Y; Zhou W; Li W
Onco Targets Ther; 2017; 10():2281-2287. PubMed ID: 28490885
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
